From 2004-2007 he worked as an instructor in oncology at Harvard Medical School, USA, where he identified novel biomarkers and drug targets for cancer treatment.
In August 2007 he joined Almac Diagnostic Services as the director of a CLIA compliant diagnostics laboratory and has been involved in the biomarker design for several international clinical trials. In 2012 he established a research group in Queen’s University Belfast focussed on various aspects of stratified medicine.
Richard Kennedy currently sits on the CR-UK new agents committee, MRC Biomarkers steering group, the National Cancer Clinical Trials Steering Group, the Enterprise Ireland Technology assessment panel and the all-Ireland Breast Cancer Predict Consortium. Previously he was a member of the CR-UK biomarker steering group and the Breast Cancer Campaign scientific advisory board.